At termination, BCMA+ tumor cells were only detectable in the bone marrow of the original PBS-treated mice (day 97) and the tumor only control mice for the re-challenge experiment (day 51 after re-challenge) (Fig. 7L). This evidence concerns the gene TNFRSF17 and neoplasm.